Introduction

The basic mechanism of action of the highly toxic nerve agents - irreversible inhibition of acetylcholinesterase (AChE, EC 3.1.1.7), that results in the accumulation of endogenous acetylcholine (ACh) in synaptic cleft and paralysis of nerve impulse transmission in the central and peripheral nervous system, is well known (1, 13). Nevertheless, there are still problems with the effective treatment of acute poisoning with them (2,5).

Conventional antidotal treatment of nerve agent poisoning consists of cholinolytic drugs (preferably atropine) to counteract the effects of accumulated ACh at the receptors and oximes (preferably pralidoxime and obidoxime) to reactivate nerve agent-inhibited AChE (5,13). Generally, conventional oximes (pralidoxime, obidoxime, methoxime) have been considered to be adequate against some nerve agents such as sarin and VX but rather ineffective against other nerve agents such as soman and cyclosin (11,15,16). The differences in the oxime effectiveness are mainly due to the variation in aging rates; the process by which nerve agent-inhibited AChE is converted to a form that cannot be reactivated by oximes (2,13). Soman-inhibited AChE cannot be reactivated within minutes following poisoning and therefore the treatment of soman poisoning is much more difficult than VX or sarin poisoning (2,9).

This fact led to the synthesis of a series of bisquaternary oximes, designated „H-oximes”, that in combination with anticholinergic drugs have been relatively successful in antagonizing soman poisoning (9,15). Among the H-oximes, HI-6 and HL6-7 have been the most promising against nerve agent poisoning (8,14) and consequently have been the best studied. New asymmetric bispyridinium oxime, synthesized in our laboratory, designated BI-6 1-[4-carbamoylpyridinium]-4-[2-hydroxyiminomethylpyridinium]-2-buten dibromide also belongs to H-oximes (3).

The purpose of this study was to compare the therapeutic effectiveness of new oxime BI-6 and other H-oximes as well as conventional oximes against supralethal poisoning with chosen nerve agents (soman, sarin, cyclosin) in mice.

Methods

Male mice (19 - 24g) obtained from Konárovice were housed in an air-conditioned room (20-22°C) on 12-h light/12-h dark cycles and were allowed access to food and tap water ad libitum. The principles of laboratory animal care were followed and the handling of animals was made under the supervision of the Ethics Committee of the Medical Faculty of Charles University and the Military Medical Academy (Hradec Králové).

To evaluate the maximal treatment efficacy of tested oximes, we have used their prophylactic administration (5 minutes before nerve agent). The prophylactic treatment should give better results than treatment after poisoning and reduces the nerve agent-specific influence of aging.

We determined the i.m. LD50 values of oximes in mice and i.m. oxime doses that are sufficient for the 50% survival of mice poisoned with supralethal doses (2xLD3) of nerve agents (ED50 values). The values were estimated by probit analysis based on 24h mortality data in at least five
groups of six animals each (17). For ED50 determination, the oximes were administered i.m. in the same solution as atropine sulfate (21 mg/kg). The administration of atropine alone failed to prevent the mortality following exposure to all three nerve agents tested. In the end, the safety ratio (SR; LD50/ED50) of each oxime was evaluated.

**Results**

The LD50 values of all oximes tested are shown in Table 1. New oxime BI-6 is less toxic for mice than conventional oximes pralidoxime and obidoxime but significantly more toxic than other H oximes (HI-6, HLö-7).

**Table 1: Toxicity parameters of oximes tested**

| OXIMES  | LD50 (mg/kg) |
|---------|--------------|
| Pralidoxime | 230.5 (192.2 - 276.5) |
| Obidoxime | 188.4 (156.3 - 208.0) |
| Methoxime | 641.8 (590.5 - 716.0) |
| BI-6 | 266.3 (248.5 - 283.4) |
| HI-6 | 671.3 (627.4 - 718.3) |
| HLö-7 | 356.0 (293.0 - 431.0) |

The ED50 and SR values of oximes tested are shown in Table 2 - 4. In the case of soman poisoning, there are big differences in the efficacy between conventional oximes and H oximes. While all conventional oximes (pralidoxime, obidoxime, methoxime) are practically ineffective against supralethal dose of soman (ED50 values are too high), H oximes are sufficiently effective in relatively small doses. The new oxime BI-6 is a little less effective than other H oximes (Table 2).

**Table 2: Prophylactic antidotal potency (ED50) and safety ratio (SR) in soman poisoned mice (2xLD50)**

| OXIMES  | ED50 (mg/kg) | SR (LD50/ED50) |
|---------|--------------|----------------|
| Pralidoxime | 92.5 (81.4 - 105.1) | 2.5 |
| Obidoxime | > 120 | < 1.6 |
| Methoxime | 105.7 (95.5 - 117.1) | 6.1 |
| BI-6 | 16.7 (10.4 - 26.7) | 16.0 |
| HI-6 | 3.5 (2.4 - 5.0) | 192.9 |
| HLö-7 | 3.5 (2.4 - 4.6) | 106.9 |

In the case of sarin poisoning, practically all tested oximes are sufficiently effective against supralethal dose of sarin in relatively low doses. The oxime BI-6 is a little less effective than other H oximes again (Table 3).

**Table 3: Prophylactic antidotal potency (ED50) and safety ratio (SR) in sarin poisoned mice (2xLD50)**

| OXIMES  | ED50 (mg/kg) | SR (LD50/ED50) |
|---------|--------------|----------------|
| Pralidoxime | 10.45 (7.50 - 14.60) | 22.1 |
| Obidoxime | 1.56 (1.07 - 2.28) | 120.8 |
| Methoxime | 0.78 (0.61 - 1.00) | 822.8 |
| BI-6 | 1.97 (1.56 - 2.50) | 135.2 |
| HI-6 | 0.47 (0.38 - 0.57) | 1428.3 |
| HLö-7 | 0.16 (0.12 - 0.22) | 2225.0 |

In the case of cyclosin intoxication, the conventional oximes are significantly less effective than H oximes. Their ED50 values are relatively high although not so high as in the case of poisoning with soman. The oxime BI-6 seems to be as effective as other H oximes against cyclosin (Table 4).

**Table 4: Prophylactic antidotal potency (ED50) and safety ratio (SR) in cyclosin poisoned mice (2xLD50)**

| OXIMES  | ED50 (mg/kg) | SR (LD50/ED50) |
|---------|--------------|----------------|
| Pralidoxime | 52.99 (36.70 - 76.50) | 4.4 |
| Obidoxime | 18.18 (11.20 - 29.50) | 10.4 |
| Methoxime | 4.19 (2.41 - 7.29) | 153.2 |
| BI-6 | 0.51 (0.30 - 0.86) | 522.2 |
| HI-6 | 0.12 (0.08 - 0.20) | 5594.2 |
| HLö-7 | 0.45 (0.37 - 0.56) | 791.1 |

**Discussion**

Our results clearly demonstrate large differences in the efficacy between conventional oximes and H oximes, especially against soman and cyclosin. The therapeutic efficacy of oximes depends on the type of nerve agent in spite of prophylactic administration of antidotes that reduces the nerve agent - specific influence of aging. It means that other aspects of nerve agent toxidynamics than aging can influence on the efficacy of oximes (2).

With conventional oximes, soman or cyclosin poisoned mice could only be effectively treated with high doses (usually more than 20% LD50) but not with doses supposed for humans (approximately 2% LD50), with the exception of methoxime against cyclosin. Only H oximes (especially HI-6 and HLö-7) were effective at „human“ doses in poisoned mice regardless of the nerve agent used (10). The new oxime BI-6 is sufficiently effective at „human“ dose in mice intoxicated with cyclosin but not with soman, where LD50 value corresponds to 6% LD50.

The much higher therapeutic potency of H oximes in comparison with conventional oximes may be caused not only by the higher reactivating efficacy (6,9) but also by other antidotal mechanisms based on antimuscarinic, antinicotinic and ganglion blocking actions as well as on restoration of neuromuscular blockade and beneficial effects on cardiovascular and respiratory systems (4,8-12,18,19).

In conclusion, the present results indicate that only H oximes (HI-6, HLö-7) are effective against supralethal intoxication of mice when given in very low doses corresponding to those proposed for humans, regardless of the nerve...
agent used. The new oxime BI-6, synthesized in our laboratory, is as effective as other H-oximes tested against sarin and cyclosin, but a little less efficacious against soman. Thus both H oximes (HI-6 and HLö-7) may be attractive compounds to develop for use against nerve agent poisoning in spite of their relative instability in aqueous solution and relative insolubility (7,14). They are being considered to replace the oximes used until now in military injectors although general decision to replace the currently used oximes by H oximes could not be reached (19).

Acknowledgements
The author expresses his appreciation to Mrs. J Petrová and Mrs. J. Uhlířová for their technical assistance and help with statistical evaluation. Special thanks are due to Dipl. ing. J. Bielavský for synthesis of the new oxime BI-6.

References
1. Bajgar J. Biological monitoring of exposure to nerve agent. Br J Ind Med 1992;49:648-53.
2. Bajgar J. Present views on toxidynamics of soman poisoning. Acta Med (Hradec Králové), 1996;39:101-5.
3. Bielavský J, Kassa J, Elsnerová I, Dejmek L. Cholinesterase reactivators derived from pyridine-2-carbaldoxime. Collect Czech Chem Commun 1998;63:in press.
4. Chen H-Ch, Bai D-Y, Jiang Y-P. Effects of HI-6 on muscle acetylcholine receptor: analysis on minimal reaction model. Acta Pharmacol Sin 1996;17:428-31.
5. Dawson RM. Review of oximes available for treatment of nerve agent poisoning. J Appl Toxicol 1994;14:317-31.
6. de Jong LPA, Verhagen MAA, Langenberg JP, Hagedorn I, Löffler M. The bispyridinium-dioxime HLö-7, a potent reactivator for acetylcholinesterase inhibited by the stereoisomers of tabun and soman. Biochem Pharmacol 1989;38:633-40.
7. Eyer P, Ladstetter B, Schofer W, Sonnenbichler J. Studies on the stability and decomposition of the hagedorn oxime HLö-7 in aqueous solution. Arch Toxicol 1989;63:59-67.
8. Eyer P, Hagedorn I, Klimmek R, Lippstreu P, Löffler M, Oldiges H, Spöhrer U, Steidl J, Szinicz L, Worek F. HLö-7 dimethansulfonate, a potent bispyridinium-dioxime against anticholinesterases. Arch Toxicol 1992;66:603-21.
9. Kassa J. Comparison of efficacy of two oximes (HI-6 and obidoxime) in soman poisoning in rats. Toxicology 1995;101:167-74.
10. Kassa J, Cabal J, Bajgar J, Szinicz L. The choice: HI-6, pralidoxime or obidoxime against nerve agents? ASA Newslett 1997;97:4:16-18.
11. Koplovitz I, Stewart JR. A comparison of the efficacy of HI-6 and 2-PAM against soman, tabun, sarin and VX in the rabbit. Toxicol Lett 1994;70:269-79.
12. Kostenis E, Cid HMB, Holzgrabe U, Mohr K. Evidence for a multiple binding mode of bispyridinium-type allosteric modulators of muscarinic receptors. Eur J Pharmaco 1996;314:385-92.
13. Mars TC. Organophosphate poisoning. Pharmacol Ther 1993;58:51-66.
14. Rousseaux CG, Dua AK. Pharmacology of HI-6, an H-series oxime. Can J Physiol Pharmacol 1989;67:1183-9.
15. Shih T-M, Whalley ChE, Valdes JJ. A comparison of cholinergic effects of HI-6 and pralidoxime-2-chloride (2-PAM) in soman poisoning. Toxicol Lett 1991;55:131-47.
16. Shih T-M. Comparison of several oximes on reactivation of soman-inhibited blood, brain and tissue cholinesterase activity in rats. Arch Toxicol 1993;67:637-46.
17. Tallarida R, Murray R. Manual of pharmacological calculation with computer programs. Springer-Verlag, New York 1987; p. 145.
18. Tattersall JEH. Ion channel blockade by oximes and recovery of diaphragm muscle from soman poisoning in vitro. Br J Pharmacol 1993;108:1006-15.
19. van Helden HPM, Busker RW, Melchers BPC, Bruijnzel PLB. Pharmacological effects of oximes: how relevant are they? Arch Toxicol 1996;70:779-86.

Submitted January 1998. Accepted January 1998.

Doc. MUDr. Jiří Kassa, CSc., Purkyně Military Medical Academy, 500 01 Hradec Králové, Czech Republic.